Woodline Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Woodline Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.16M	Hold	100,478	–	–	0.01%	785
2026 Q1	$2.49M	Sell	100,478 -50,169	-33%	-$1.2M	0.01%	780
2025 Q4	$3.52M	Buy	150,647 +169	+0.1%	+$3.77K	0.01%	691
2025 Q3	$2.96M	Hold	150,478	–	–	0.01%	670
2025 Q2	$3.27M	Sell	150,478 -56,000	-27%	-$1.32M	0.02%	636
2025 Q1	$5.01M	Sell	206,478 -46,491	-18%	-$1.05M	0.03%	510
2024 Q4	$5.28M	Sell	252,969 -53,489	-17%	-$1.15M	0.04%	476
2024 Q3	$6.09M	Sell	306,458 -197,277	-39%	-$3.66M	0.05%	366
2024 Q2	$7.8M	Sell	503,735 -23	-0%	-$358	0.07%	282
2024 Q1	$8.03M	Buy	+503,758	New	+$7.59M	0.07%	300
2023 Q3	–	Sell	-253,325	Closed	-$3.4M	–	618
2023 Q2	$3.4M	Buy	+253,325	New	+$3.65M	0.04%	355

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Woodline Partners's CPRX Position: Q2 2026 in Review

Woodline Partners held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 100,478 shares worth $3.16M. The position accounts for 0.01% of the portfolio, ranked #785.

Woodline Partners first reported a position in CPRX in Q2 2023 and has held it in 11 quarters since. The position peaked at $8.03M in Q1 2024. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Woodline Partners held 100,478 shares of Catalyst Pharmaceutical worth $3.16M as of Q2 2026.
Woodline Partners left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #785 holding.
Woodline Partners first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 11 quarters since.
Woodline Partners's Catalyst Pharmaceutical position peaked at $8.03M in Q1 2024.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.